INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37201, 29683, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37202, 29771, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37203, 29772, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37204, 29773, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37205, 29774, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37206, 30038, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37207, 30039, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37208, 30040, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37209, 30293, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37210, 31806, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37211, 32614, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37212, 32615, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37213, 32616, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37214, 32617, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37215, 32618, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37216, 32619, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37217, 51, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37218, 1860, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37219, 2216, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37220, 2217, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37221, 2218, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37222, 2220, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37223, 2268, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37224, 2286, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37225, 2287, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37226, 2289, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37227, 2291, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37228, 4230, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37229, 4231, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37230, 6830, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37231, 7503, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37232, 8047, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37233, 9177, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37234, 9939, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37235, 9940, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37236, 11643, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37237, 12639, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37238, 12640, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37239, 12641, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37240, 12709, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37241, 12941, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37242, 15995, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37243, 15996, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37244, 15998, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37245, 16047, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37246, 16048, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37247, 16049, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37248, 16064, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37249, 16065, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37250, 16067, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37251, 16068, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37252, 17727, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37253, 18326, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37254, 18327, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37255, 18328, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37256, 18369, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37257, 18370, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37258, 18371, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37259, 18372, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37260, 18373, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37261, 18495, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37262, 18751, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37263, 21055, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37264, 21338, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37265, 22008, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37266, 22615, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37267, 22616, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37268, 23412, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37269, 23413, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37270, 23986, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37271, 23988, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37272, 23989, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37273, 25640, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37274, 25641, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37275, 25642, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37276, 25643, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37277, 26235, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37278, 26236, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37279, 28462, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37280, 28463, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37281, 28470, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37282, 28471, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37283, 28562, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37284, 28563, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37285, 28564, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37286, 28565, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37287, 28566, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37288, 29602, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37289, 29603, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37290, 29683, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37291, 29771, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37292, 29772, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37293, 29773, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37294, 29774, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37295, 30038, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37296, 30039, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37297, 30040, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37298, 30293, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37299, 31806, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37300, 32614, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '', 'DDInter', 0);
